Research programme: osteomyelitis prodrug therapies - The Medicines Company

Drug Profile

Research programme: osteomyelitis prodrug therapies - The Medicines Company

Alternative Names: TT-99000520; TT-99000559; TT-99000647; TT-99000665

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targanta Therapeutics Corporation
  • Class Fluoroquinolones
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Osteomyelitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Osteomyelitis(Prevention) in Canada (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Osteomyelitis(Prevention) in Canada (SC)
  • 01 Oct 2007 Preclinical trials in Osteomyelitis in Canada (parenteral route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top